Peter Fasolo - Johnson Johnson President

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 35px;;'>JNJ</div>
JNJ -- USA Stock  

Earnings Report: April 21, 2020  

Dr. Peter M. Fasolo Ph.D. is Chief Human Resource Officer, Executive Vice President of the Company. Dr. Fasolo joined the Company in 2004 as Vice President, Worldwide Human Resources for Cordis Corporationrationration, a subsidiary of the Company, and was subsequently named Vice President, Global Talent Management for the Company. He left Johnson Johnson in 2007 to join Kohlberg Kravis Roberts Co. as Chief Talent Officer. Dr. Fasolo returned to the Company in 2010 as the Vice President, Global Human Resources, and in 2011, he became a member of the Executive Committee. In April 2016, he was named Executive Vice President, Chief Human Resources Officer
Age: 55  President Since 2016      
732 214-0332
Fasolo has responsibility for global talent, recruiting, diversity, compensation, benefits, employee relations and all aspects of the human resources agenda for the Company.

Peter Fasolo Latest Insider Activity

Management Efficiency

The company has Return on Asset of 0.01 % which means that on every $100 spent on asset it made $0.01 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.02 % implying that it generated $0.02 on every 100 dollars invested.
The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Paul HudsonAstrazeneca PLC
Joseph CaldarellaBristol Myers Squibb Company
Shah HussainGlaxoSmithKline PLC
Willie DeeseMerck Company
Mark MallonAstrazeneca PLC
Alexander MackenziePfizer
John ElickerBristol Myers Squibb Company
Andrew ChengGilead Sciences
Ann PowellBristol Myers Squibb Company
Lidia FonsecaPfizer
Mark FishmanNovartis AG
Menelas PangalosAstrazeneca PLC
Laura HamillGilead Sciences
Stephen FryEli Lilly And Company
Roger PerlmutterMerck Company
Matthew WalshAllergan Plc
Iskra ReicAstrazeneca PLC
Darren CarrollEli Lilly And Company
Michael HarringtonEli Lilly And Company
Jan LundbergEli Lilly And Company
Karen SantiagoBristol Myers Squibb Company

Entity Summary

Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 135100 people.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 135,100 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent Director
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
D Davis, Independent Director
Hubert Joly, Director
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Susan Lindquist, Independent Director
Mark Weinberger, Director

Stock Performance Indicators

Current Sentiment - JNJ

Johnson Johnson Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Johnson Johnson. What is your judgment towards investing in Johnson Johnson? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also see Risk vs Return Analysis. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.